/
Our mission is to expand access to novel molecular diagnostic testing, most immediately in the transplanted organ rejection testing category. We are developing molecular diagnostic test kits designed to empower our customers to run their own tests in-house to participate in the patient-care value chain, which is counter-positioned with the send-out-testing central laboratory model.
The business is unprofitable at the operating level (-1260.76% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 115.6% YoY with margins expanding 1984.4pp.
ROIC dropped from -401.35% to -1173.90%, capital efficiency is deteriorating. Negative free cash flow of -$25M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$2M
▲ +115.6% YoY
Net Income (TTM)
-$48M
▲ +17.2% YoY
Op. Margin
-2500.67%
▲ +1984.4pp YoY
ROIC
-1144.99%
▼ -772.5pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$27M
▼ -19.6% YoY
Op. Cash Flow (TTM)
-$24M
▼ -7.2% YoY
Net Debt
-$25M
Net Cash Position
Cash & Equiv.
$28M
5Y CAGR: +27.2%
Continue Research